Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repotrectinib - Bristol-Myers Squibb

Next Previous
Drug Profile

Repotrectinib - Bristol-Myers Squibb

Alternative Names: AUGTYRO; BMS-986472; Ropotrectinib; TPX 0005; ZL-2308

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TP Therapeutics
  • Developer Bristol-Myers Squibb; Turning Point Therapeutics; ZAI Lab
  • Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein tyrosine kinase inhibitors; Janus kinase 2 inhibitors; ROS1 protein inhibitors; Src-family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer; Solid tumours
  • Phase II Adenocarcinoma
  • Phase I/II CNS cancer; Lymphoma
  • Preclinical Multiple myeloma

Most Recent Events

  • 21 Apr 2025 Preregistration for Solid tumours (In adults, Late-stage disease, Metastatic disease) in China (PO) before April 2025
  • 21 Apr 2025 National Medical Products Administration accepts sNDA for Solid tumours (In adults, Late-stage disease, Metastatic disease) in China (PO)
  • 01 Apr 2025 Onward Point Therapeutics withdraws a phase I drug-drug interaction trial for Solid tumors (Late stage disease, Metastatic disease) in USA (PO, Capsule) due to insufficient enrollment (NCT05828303)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top